The effect of papaverine on morphologic differentiation, proliferation and invasive potential of human prostatic cancer LNCaP cells

Background: Intracellular cyclic adenosine monophosphate (AMP) level changes are thought to play an important role in inhibiting cell proliferation and inducing differentiation in several types of cells. It has been reported that cyclic AMP analogs induce terminal differentiation in human prostate cancer cells. Consequently, phosphodiesterase inhibitors may be useful in delineating the role of cyclic AMP in the differentiation of these cells. Therefore, the effect of phosphodiesterase inhibitors on morphologic differentiation, proliferation and invasive potential of human prostate cancer cells was investigated.

[1]  R. Warrell,et al.  Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. , 1992, Cancer research.

[2]  P. Greengard,et al.  Cyclic nucleotide-dependent protein kinases. IV. Widespread occurrence of adenosine 3',5'-monophosphate-dependent protein kinase in various tissues and phyla of the animal kingdom. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Kemshead,et al.  Morphological differentiation of human neuroblastoma cell lines by a new synthetic polyprenoic acid (E5166). , 1987, Cancer research.

[4]  E. Jaffe,et al.  Transcriptional inactivation of c-myc and the transferrin receptor in dibutyryl cyclic AMP-treated HL-60 cells , 1987, Molecular and cellular biology.

[5]  A. Bloch.  Induced cell differentiation in cancer therapy. , 1984, Cancer treatment reports.

[6]  K. Prasad,et al.  Role of cyclic amp in differentiation of human neuroblastoma cells in culture , 1975, Cancer.

[7]  J. Scott.  Cyclic nucleotide-dependent protein kinases. , 1991, Pharmacology & therapeutics.

[8]  J. Mulcahy,et al.  Carcinoma of the prostate. , 1978, The Journal of the Kentucky Medical Association.

[9]  C. Dinney,et al.  Metastatic model for human prostate cancer using orthotopic implantation in nude mice. , 1992, Journal of the National Cancer Institute.

[10]  Y. Bang,et al.  Cyclic AMP induces transforming growth factor beta 2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Imashuku,et al.  Characterization and activation of cyclic adenosine 3′:5′‐monophosphate‐dependent protein kinase in C1300 murine neuroblastoma clones growing in vivo , 1982, International journal of cancer.

[12]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[13]  M. Ui,et al.  An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small-volume samples from blood and tissue. , 1977, Biochemical medicine.

[14]  Y. Cho‐Chung.  Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. , 1990, Cancer research.

[15]  R. Virag.  INTRACAVERNOUS INJECTION OF PAPAVERINE FOR ERECTILE FAILURE , 1982, The Lancet.

[16]  D. Friedman.  Role of cyclic nucleotides in cell growth and differentiation. , 1976, Physiological reviews.

[17]  Y. Bang,et al.  Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Das,et al.  A rationale for the treatment of metastatic neuroblastoma. , 1976, Journal of the National Cancer Institute.

[19]  S. Zimmer,et al.  The effect of dibutyryl camp (dBcAMP) on morphological differentiation, growth and invasion in vitro of a hamster brain‐tumor cell line: A comparative study of dBcAMP effects in 2‐ and 3‐dimensional cultures , 1991, International journal of cancer.

[20]  D M Essayan,et al.  Cyclic nucleotide phosphodiesterases. , 2001, The Journal of allergy and clinical immunology.

[21]  D. Peehl,et al.  Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. , 1993, Endocrinology.

[22]  R. Vessella,et al.  Inhibition of tumorigenic potential and prostate‐specific antigen expression in LNCaP human prostate cancer cell line by 13‐cis‐retinoic acid , 1994, International journal of cancer.

[23]  Y. Ito,et al.  Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080. , 1995, Cancer research.